Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesImagion Biosystems Ltd

Imagion Biosystems Ltd

Healthcare Diagnostics & Research
PortfolioPortfolio WatchlistWatchlist
Company price
0.006 AUD 0.00(0%)
Last update at 2026-11-06T04:04:00Z
VOLUME
636591
Market Cap
4.81M

Momentum Score

…

Imagion Biosystems Limited operates as a medical imaging company that uses bio-safe magnetic nanoparticles to detect cancer and other diseases in Australia. The company is involved in nanotechnology; biotechnology; medical imaging using magnetic resonance; and cancer diagnostics businesses. It develops MagSense, which is in Phase 2 for the treatment of HER2 breast cancers, as well as advancing the research and development programs for prostate and ovarian cancer. It also develops PrecisionMRX, an iron oxide nanoparticle to magnetic relaxometry. The company has collaboration agreement with Wayne State University to develop optimised MRI sequences which is in Phase 2 study of for the MagSense imaging agent. Imagion Biosystems Limited was incorporated in 2016 and is based in Melbourne, Australia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.01
Low
0.01
High
52 Week Price Range
0.01
Low
0.04
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Imagion Biosystems is an Australian clinical-stage medical technology company developing magnetic nanoparticle-based imaging solutions for earlier cancer detection and intraoperative guidance. Long-term growth could be driven by positive clinical trial outcomes, regulatory approvals and eventual hospital adoption or licensing of its platform, offering potential to address unmet needs in oncology imaging.

Material risks include clinical or regulatory setbacks, lack of commercial revenue and the need for continued financing, together with competition from established imaging modalities and alternative diagnostics.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.01
Dividend Yield
-
Revenue TTM
0.57M
Revenue Per Share
0.00
Gross Profit TTM
-2.51M
Debt / Equity
-1.19
ROE
-2804.87%
Net Debt
0.72M
ROCE
165.82%
Diluted EPS TTM
-0.01

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -4.35M -2.50M -16.01M -9.81M -6.02M
Net income -4.31M -2.07M -12.47M -9.81M -8.64M
Selling general administrative - 1.74M 3.58M 5.52M 3.76M
Selling and marketing expenses - 0.88M 6.70M - -
Gross profit -0.01M 2.26M -0.28M 0.47M 0.23M
Reconciled depreciation - 0.39M 1.18M 1.11M 0.40M
Ebit -3.58M -0.75M -11.49M -9.81M -6.02M
Ebitda -3.58M -0.70M -10.30M -8.70M -5.62M
Depreciation and amortization 0.01M 0.05M 1.18M 1.11M 0.40M
Operating income -3.58M -0.76M -15.63M -9.81M -6.02M
Other operating expenses 3.58M 3.42M 16.72M 12.70M 8.87M
Interest expense 0.85M 1.14M 1.13M 0.00M 0.00M
Tax provision - 0.00M 0.00M 0.00M 0.00M
Interest income - 0.01M 0.07M 0.03M 0.01M
Net interest income - -1.13M -1.06M -0.14M 0.00M
Income tax expense -0.04M -0.44M -3.53M 0.00M 2.61M
Total revenue - 2.67M 1.08M 0.47M 0.23M
Total operating expenses 3.58M 3.02M 15.53M 12.70M 8.87M
Cost of revenue 0.01M 0.40M 5.25M - -
Total other income expense net -0.77M -1.75M -0.37M -0.00M -0.00M
Net income from continuing ops - -2.07M -12.47M -9.81M -6.02M
Net income applicable to common shares - -2.07M -12.47M -9.81M -6.02M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 2.04M 2.80M 4.59M 9.98M 14.12M
Other current assets 0.15M 0.11M 0.30M 0.13M 0.17M
Total liab 4.21M 5.09M 6.46M 5.30M 0.81M
Total stockholder equity -2.16M -2.28M -4.69M 4.68M 13.31M
Other current liab 0.45M 0.17M -5.14M 0.37M 0.33M
Common stock 65.96M 62.54M 59.31M 56.83M 56.83M
Capital stock - - - 56.83M 56.83M
Retained earnings -71.32M -67.01M -68.91M -55.84M -46.03M
Other liab - - - 0.00M 0.00M
Cash 1.85M 2.67M 0.23M 4.45M 13.39M
Total current liabilities 4.21M 5.09M 5.36M 1.73M 0.78M
Net debt 0.72M 0.18M 6.91M 0.16M -13.35M
Short term debt 2.56M 2.85M 3.55M 1.04M 0.02M
Short long term debt total 2.56M 2.85M 7.14M 4.60M 0.05M
Other stockholder equity - - - 0.88M 0.35M
Property plant equipment - - - 4.99M 0.35M
Total current assets 2.04M 2.79M 0.60M 4.99M 13.77M
Net tangible assets - - - 4.68M 13.31M
Net receivables 0.03M 0.00M 0.07M 0.09M 0.03M
Inventory - - - 0.32M 0.17M
Accounts payable 1.20M 2.07M 1.59M 0.33M 0.43M
Accumulated other comprehensive income 3.20M 2.19M 4.92M 3.69M 2.51M
Non current assets total 0.01M 0.02M 3.98M 4.99M 0.35M
Capital lease obligations - - - 4.60M 0.05M
Long term debt total - - - 3.56M 0.03M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - 0.08M -0.19M -0.47M -0.31M
Change to liabilities - - - 0.00M 0.08M
Total cashflows from investing activities - 0.08M -0.19M -0.47M -0.31M
Net borrowings - 0.72M 3.50M -0.96M -0.36M
Total cash from financing activities 3.24M 3.61M 4.29M -0.96M 5.15M
Net income -4.31M -2.07M -12.47M -9.81M -6.02M
Change in cash -0.82M 2.44M -4.22M -8.95M 0.19M
Begin period cash flow 2.67M 0.23M 4.45M 13.39M 13.20M
End period cash flow 1.85M 2.67M 0.23M 4.45M 13.39M
Total cash from operating activities -4.04M -1.27M -8.32M -8.70M -5.07M
Issuance of capital stock - 3.13M 2.38M 0.00M 5.51M
Depreciation 0.01M 0.39M 1.18M 1.11M 0.40M
Other cashflows from investing activities - 0.08M 0.00M 0.04M -0.09M
Change to account receivables -0.01M 0.07M 0.37M -0.20M -0.03M
Sale purchase of stock - 3.13M 2.38M 0.00M -0.01M
Other cashflows from financing activities - 2.93M -1.59M -0.96M -0.36M
Change to netincome - - - 0.65M 0.50M
Capital expenditures 0.00M 0.00M 0.19M 0.51M 0.22M
Change in working capital -0.74M 0.07M 2.15M 2.55M 2.63M
Stock based compensation - 0.01M 0.46M - -
Other non cash items 1.00M 0.32M 0.36M 8.70M 5.62M
Free cash flow -4.04M -1.27M -8.51M -9.21M -5.29M

Peer Comparison*

Sector: Healthcare Industry: Diagnostics & Research

Stock Name
Change
(AUD)
Price
(AUD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
IBX
Imagion Biosystems Ltd		 -
-%		 0.01 - - 8.38 3.84 5.67 -1.90
SHL
Sonic Healthcare Ltd		 0.18
0.91%		 20.06 16.16 17.21 0.90 1.15 1.36 8.10
IDX
Integral Diagnostics Ltd		 0.01
0.58%		 1.74 28.83 15.24 0.82 0.97 1.52 9.49
ACL
Australian Clinical Labs Ltd		 0.04
1.25%		 3.24 26.67 16.84 0.81 3.95 1.24 5.12
HLS
Healius Ltd		 0.01
1.01%		 0.50 - 29.24 0.26 2.08 0.94 10.14

Profile*

Imagion Biosystems Ltd

Imagion Biosystems Limited operates as a medical imaging company that uses bio-safe magnetic nanoparticles to detect cancer and other diseases in Australia. The company is involved in nanotechnology; biotechnology; medical imaging using magnetic resonance; and cancer diagnostics businesses. It develops MagSense, which is in Phase 2 for the treatment of HER2 breast cancers, as well as advancing the research and development programs for prostate and ovarian cancer. It also develops PrecisionMRX, an iron oxide nanoparticle to magnetic relaxometry. The company has collaboration agreement with Wayne State University to develop optimised MRI sequences which is in Phase 2 study of for the MagSense imaging agent. Imagion Biosystems Limited was incorporated in 2016 and is based in Melbourne, Australia.

Suite 2, Melbourne, VIC, Australia, 3000

61 3 9692 7222

https://imagionbiosystems.com

Name Title Year Born
Mr. Robert Romeo Proulx Exec. Chairman, Pres & CEO 1958
Mr. Geoff Hollis CFO & Company Sec. NA
Dr. Yalia Jayalakshmi Ph.D. Chief Devel. Officer NA
Mr. Robert Romeo Proulx Interim Executive Chairman 1958
Mr. Geoff Hollis AGIA, BComm, CA CFO & Company Secretary NA
Mr. Robert Romeo Proulx Interim Executive Chairman 1958
Mr. Geoff Hollis AGIA, BComm, CA CFO & Company Secretary NA
Mr. Robert Romeo Proulx Interim Executive Chairman 1958
Mr. Geoff Hollis AGIA, BComm, CA CFO & Company Secretary NA
Mr. Robert Romeo Proulx Interim Executive Chairman 1958

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…